BioMarin Pharma's (BMRN) Q2 Revenue Tops Views
BioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of ($2.61), may not compare to the analyst estimate of ($0.52). Revenue for the quarter came in at $300.1 million versus the consensus estimate of $278.16 million.
GUIDANCE:
BioMarin Pharma sees FY2016 revenue of $1.1-1.15 billion, versus prior guidance of $1.05-1.1 billion and the consensus of $1.09 billion.
| Item | ||||
| Provided April 28, 2016 | Updated August 4, 2016 | |||
| Total BioMarin Revenues | $1,050 to $1,100 | $1,100 to $1,150 | ||
| Vimizim Net Product Revenue | $315 to $340 | $340 to $360 | ||
| Naglazyme Net Product Revenue | $290 to $320 | Unchanged | ||
| Kuvan Net Product Revenue | $320 to $350 | $340 to $360 |
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.